238 Future studies of nutritional interventions need to measure

functional outcomes. Protein supplementation may serve as an important preventive and therapeutic intervention against functional decline, especially when implemented in frail older people with malnutrition.73, 227 and 238 When older people experience functional decline selleck antibody and lose their independence, health care costs significantly rise.239 For these reasons, it is important that studies investigating functional outcomes are undertaken when assessing efficacy and cost-effectiveness of specific interventions. To ensure appropriate care, it is likewise important to quantify functional capacity in relationship to needs for supportive social services. Vulnerable populations, such as those living in residential care or with dementia, should also not be excluded a priori from studies on the topic. For this article on protein nutrition for older people, members of the PROT-AGE Study Group reviewed an extensive medical literature and compiled evidence

to show that getting adequate dietary protein is important to maintaining functionality. We found that optimal protein intake for an older adult is higher than the level currently recommended for adults of all ages.1, 2 and 3 New evidence shows that higher dietary protein ingestion is beneficial to support good health, promote recovery from illness, and maintain functionality in older adults.5, 6, 7, 8, 9 and 10 Based on our findings, we made updated Ion Channel Ligand Library solubility dmso recommendations for protein intake. Key PROT-AGE recommendations for dietary protein intake in older adults • To maintain physical function, older people need more dietary protein than do younger people; older people should consume an average daily intake at least in the range of 1.0 to 1.2 g/kg BW/d. Interleukin-3 receptor The PROT-AGE team thanks Cecilia Hofmann, PhD, for her valuable assistance with efficient compilation of the medical literature and with editing this systematic review. “
“Deep vein thrombosis (DVT) and pulmonary embolism (PE) are separate but related aspects of the disease process of venous thromboembolism (VTE).1 DVT of the lower extremities

is the most-frequent manifestation,2 whereas PE, the most urgent and serious, typically results from sudden occlusion of pulmonary arteries by a thrombus originating in the pelvis or calf.1 VTE has been described as a “silent killer”; most DVT cases are asymptomatic, and PE is often undetected until an autopsy is performed.3 Postevent mortality rates of 7% and 13% have been reported at 1 month4 and 11% and 15% at 6 months for DVT and PE, respectively.5 Acquired risk factors for VTE include previous VTE, frailty, cancer, hospitalization, surgery, advanced age, venous trauma, immobilization, estrogen therapy, inherited/acquired hypercoagulable state, acute medical illness, pregnancy, antiphospholipid antibodies, and several other implicated factors.